KR20230117576A - Ha-1 항원을 인식하는 결합 단백질 및 이의 용도 - Google Patents

Ha-1 항원을 인식하는 결합 단백질 및 이의 용도 Download PDF

Info

Publication number
KR20230117576A
KR20230117576A KR1020237018962A KR20237018962A KR20230117576A KR 20230117576 A KR20230117576 A KR 20230117576A KR 1020237018962 A KR1020237018962 A KR 1020237018962A KR 20237018962 A KR20237018962 A KR 20237018962A KR 20230117576 A KR20230117576 A KR 20230117576A
Authority
KR
South Korea
Prior art keywords
cell
tcr
binding protein
cells
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018962A
Other languages
English (en)
Korean (ko)
Inventor
리부 나야르
개빈 맥베스
소날 장갈웨
몰리 엠. 주레윗츠
앤드류 에스. 바신스키
치카이 쑤
앙투안 제이. 부도
토마즈 쿨라
Original Assignee
티스캔 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티스캔 테라퓨틱스, 인크. filed Critical 티스캔 테라퓨틱스, 인크.
Publication of KR20230117576A publication Critical patent/KR20230117576A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
KR1020237018962A 2020-11-06 2021-11-08 Ha-1 항원을 인식하는 결합 단백질 및 이의 용도 Pending KR20230117576A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063110851P 2020-11-06 2020-11-06
US63/110,851 2020-11-06
US202063111462P 2020-11-09 2020-11-09
US63/111,462 2020-11-09
US202063129804P 2020-12-23 2020-12-23
US63/129,804 2020-12-23
US202163175350P 2021-04-15 2021-04-15
US63/175,350 2021-04-15
PCT/US2021/058382 WO2022099100A2 (en) 2020-11-06 2021-11-08 Binding proteins recognizing ha-1 antigen and uses thereof

Publications (1)

Publication Number Publication Date
KR20230117576A true KR20230117576A (ko) 2023-08-08

Family

ID=81458633

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018962A Pending KR20230117576A (ko) 2020-11-06 2021-11-08 Ha-1 항원을 인식하는 결합 단백질 및 이의 용도

Country Status (10)

Country Link
US (1) US20230398217A1 (https=)
EP (1) EP4240490A4 (https=)
JP (1) JP2023549765A (https=)
KR (1) KR20230117576A (https=)
AU (3) AU2021323388C1 (https=)
CA (1) CA3197255A1 (https=)
IL (1) IL302616A (https=)
MX (1) MX2023005179A (https=)
TW (1) TW202227499A (https=)
WO (1) WO2022099100A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4633671A1 (en) * 2022-12-14 2025-10-22 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
AU2025202444A1 (en) * 2024-04-08 2025-10-23 Tscan Therapeutics, Inc. Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds
AU2025202443A1 (en) * 2024-04-08 2025-10-23 Tscan Therapeutics, Inc. Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
WO2025231299A1 (en) * 2024-05-02 2025-11-06 Fred Hutchinson Cancer Center Tcr t cell therapy targeting ha-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390011A1 (ru) * 2010-07-28 2013-07-30 Иммьюнокор Лтд. Т-клеточные рецепторы
CA3035075A1 (en) * 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
CN112585162B (zh) * 2018-08-06 2025-01-28 基因医疗免疫疗法有限责任公司 Ha-1特异性t细胞受体及其用途
NL2021789B1 (en) * 2018-10-10 2020-05-14 Academisch Ziekenhuis Leiden Binding proteins specific for HA-1H and uses thereof

Also Published As

Publication number Publication date
EP4240490A4 (en) 2025-06-18
MX2023005179A (es) 2023-07-13
EP4240490A2 (en) 2023-09-13
AU2021323388B2 (en) 2022-07-28
TW202227499A (zh) 2022-07-16
CA3197255A1 (en) 2022-05-12
WO2022099100A2 (en) 2022-05-12
US20230398217A1 (en) 2023-12-14
WO2022099100A3 (en) 2022-06-16
AU2022241563A1 (en) 2022-11-03
JP2023549765A (ja) 2023-11-29
AU2026200575A1 (en) 2026-02-19
IL302616A (en) 2023-07-01
AU2021323388C1 (en) 2022-10-27
AU2021323388A1 (en) 2022-05-26
AU2022241563B2 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
AU2021323388C1 (en) Binding proteins recognizing HA-1 antigen and uses thereof
AU2022268347B2 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
US20240197877A1 (en) Binding proteins recognizing ha-2 antigen and uses thereof
US20230272049A1 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof
TW202304964A (zh) Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途
US20250249039A1 (en) Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
AU2025200025A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
AU2026202663A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
JPWO2023086477A5 (https=)
CN116940593A (zh) 识别ha-1抗原的结合蛋白及其用途
CN118103049A (zh) 识别ha-2抗原的结合蛋白及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230605

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241105

Comment text: Request for Examination of Application